Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-108

"Sounds like we sold the entire thing but get to manufacture for 3 years."
That's an interesting observation bhs. The announcement states that "Admedus retains manufacturing rights for up to three years" and "Admedus retains sole-control on all intellectual property for the underlying ADAPT technology".
It does beg the question of what happens after 3 years. Hopefully it will be a successful partnership and will continue for many more years. Reminds me of the old story of going to the dentist and as he is about to start drilling you take a firm grip of his private parts and say - now were not going to hurt each other are we. I think there will need to be a lot of trust between the companies.